Company: CYTK
Filing Date: 2025-03-31
Form Type: PRE 14A
Source: 0001140361-25-011212
Chunk: 64

Company: CYTOKINETICS INC
Filing Date: 2025-03-31
Form: PRE 14A
Chunk 64
---
 Certification Date”) and 50% of the Milestone I PSUs would vest on the 1-year anniversary of the Milestone I Certification Date. |

| • | If the Compensation Committee certified that (x) the Aficamten NDA was submitted to FDA on or before the last calendar day of the third quarter of 2024, and (y) the Aficamten NDA was accepted for filing by FDA on or before the last calendar day of the fourth quarter of 2024, and (z) FDA did not grant the Company priority review for the Aficamten NDA, 50% of the Milestone I PSUs would be deemed forfeited and cancelled and 50% of the Milestone I PSUs would be earned and they would vest as follows: 25% of the Milestone I PSUs would vest on the Milestone I Certification Date and 25% of the Milestone I PSUs would vest on the 1-year anniversary of the Milestone I Certification Date. |

| • | If the Compensation Committee certified that (x) the Aficamten NDA was submitted to FDA on or after the first calendar day of the fourth quarter of 2024 but on or before the last calendar day of the fourth quarter of 2024, and (y) the Aficamten NDA was accepted for filing by FDA on or before the last calendar day of the first quarter of 2025, 75% of the Milestone I PSUs would be deemed forfeited and cancelled and 25% of the Milestone I PSUs would be earned and they would vest as follows: 12.5% of the Milestone I PSUs would vest on the Milestone I Certification Date and 12.5% of the Milestone I PSUs would vest on the 1-year anniversary of the Milestone I Certification Date. |

| • | If the Compensation Committee did not certify the satisfaction of the performance condition in accordance with the above, 100% of the Milestone I PSUs would be deemed forfeited and cancelled. |

In December 2024, the Compensation Committee certified that (x) the Aficamten NDA was submitted to FDA on or before the last calendar day of the third quarter of 2024, (y) the Aficamten NDA was accepted for filing by FDA on or before the last calendar day of the fourth quarter of 2024, and (z) FDA did not grant the company priority review